Streetbeat News

Revenues

INTT

inTEST Corporation has updated its full year 2024 revenue guidance following the acquisition of Alfamation, raising the forecast from $125M-$130M to $145M-$155M. The acquisition is expected to be dilutive to 2024 earnings per diluted share but accretive to non-GAAP adjusted EPS, mainly due to amortization of intangible assets. The impact on Q1 2024 results is expected to be nominal.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 8:23 pm

PHX

PHX Minerals (NYSE:PHX) reported Q1 2024 earnings of $0.07 per share, meeting analyst estimates. Quarterly sales were $11.783M, surpassing the $10.382M estimate by 13.50%, but represented a 35.51% decrease from the previous year's $18.270M.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 8:22 pm

SWIM

Latham Group (NASDAQ:SWIM) reported Q4 sales of $90.867M, surpassing the analyst consensus estimate of $87.207M by 4.20%. However, this represents a 15.80% decrease from the previous year's sales of $107.924M.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 8:20 pm

INTT

inTEST Corporation has acquired Alfamation S.p.A., with Alfamation set to join inTEST's Electronic Test division. Alfamation reported annual revenue of approximately $25 million in 2023 and had a backlog of $15 million as of December 31, 2023. The acquisition is expected to be accretive to inTEST's earnings in 2025, following Alfamation's history of double-digit annual revenue growth.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 8:20 pm

DOMA

Doma Holdings reported Q4 sales of $84.61M, surpassing the analyst consensus estimate of $69.42M by 21.88%, but marking a 12.20% decrease from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 8:17 pm

BRT

BRT Apartments Corp. (NYSE:BRT) reported Q4 2023 FFO of $0.38 per share, surpassing the $0.28 estimate by 35.71%. However, their sales of $23.51M fell short of the $23.82M estimate by 1.31%, marking a 3.51% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 8:16 pm

SKIN

The Beauty Health Company (SKIN) projects Q1 revenue to be between $77M-$83M, below the estimated $85.53M, and anticipates flat to low-single digit percentage growth for FY24. The company expects a seasonally low Q1 due to increased sales and marketing investments, with an adjusted EBITDA of ($6)-($9) million for Q1 and over $40 million for FY24, assuming stable market conditions and excluding unforeseen events or transactions.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 8:12 pm

MXCT

MaxCyte expects its FY24 core business revenue to show 0-5% growth compared to 2023, with SPL Program-related revenue projected at $3M. The company anticipates ending 2024 with $175M in total cash, cash equivalents, and investments. This outlook excludes SPL Program-related revenue from Vertex/CRISPR's CASGEVYTM and accounts for a challenging year-over-year comparison due to a client milestone recognized in 2023.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 8:09 pm

PRPL

Purple Innovation projects its FY24 revenue to be in the range of $540M-$560M, which is around the current estimate of $546.53M.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 8:07 pm

CLOV

Clover Health Investments (CLOV) reported Q4 sales of $510.30M, surpassing the analyst consensus estimate of $480.25M by 6.26%. However, this represents a 43.22% decrease from the same period last year's sales of $898.79M.

Portfolio Pulse from Happy Mohamed

March 12, 2024 | 8:06 pm